for use in the clinic. In addition to the in vivo studies, certain toxicity assessments (e.g., mutagenicity) are carried out in vitro using cell culture systems.
The objectives of individual studies are rarely as simple as compiling data that inherently supports/rejects development of the drug candidate. Although some studies can be crafted with such a "go/no go" outcome defined, the goal is more often to better characterize and understand observed toxicities in order to minimize their impact, thus providing a way forward. For example, if a drug designed to treat anemia in cancer patients receiving chemotherapy is oncogenic, that drug series will probably be terminated. However, if an antihistamine causes stomach ulcers, there may be a chance to move forward if this liability can be abrogated in following studies by changing the dosing regimen, formulation, etc.
FLOW CYTOMETRY AND BIOMARKERS
Toxicology studies include clinical observation, clinical pathology/chemistry end point measurements, and macroscopic/microscopic pathologic examination at and postnecropsy (for terminal studies). Tissues are typically harvested at necropsy and either examined immediately (e.g., blood) or preserved (i.e., chemically fixed and/or frozen) for future examination. Various tissues collected provide many opportunities to apply flow cytometry in preclinical toxicology/safety assessment. Obviously, body fluids such as peripheral blood and urine, routinely collected for clinical pathologic analyses, are amenable to flow cytometric analysis. Perhaps just as obvious, isolation of hematopoietic cells from bone marrow, spleen, and lymph nodes for flow cytometry is simply achieved. In general, as long as a single-cell suspension can be achieved by homogenization and/or digestion protocols, flow cytometric analysis can be performed on any solid tissue as well. Some examples of solid tissues that can be analyzed by flow cytometry include kidney, liver, eye, testis, and pancreas. Even fetal brain and whole embryos can be homogenized and single-cell suspensions prepared with appropriate protocols.
But capability does not equate with applicability; nor does it define benefit. For instance, flow cytometric analysis is superfluous in an MTD study where cell-specific information is not necessary to define dose-limiting toxicity (e.g., gastric ulceration). On the other hand, flow cytometric end points could prove to be extremely useful as correlative data in a dose range-finding study or provide the primary data in cases where a defined toxicity affects hematopoiesis or is immunomodulatory. It is also a useful technique to apply to mechanistic studies in order to identify affected cell types in a heterogeneous tissue or to measure specific effects (e.g., protein expression changes, ion flux, etc.) on select target cells. Given an appropriate analytical end point, one could argue the benefits of including flow cytometric analysis in many study designs. Preclinical toxicology may also be tasked with finding biomarkers of toxicity. It may be possible to move the drug candidate forward if a robust biomarker is available that predicts and/or correlates with pathology, regardless of the type of toxicity observed. For terminal studies in animals, this could be provided by analysis of virtually any tissue that can be obtained at necropsy. But it is highly desirable to develop a biomarker that requires minimal invasive tissue collection in order to provide the opportunity for development as a clinical biomarker as well. Flow cytometric analysis of blood often holds the potential to provide such a biomarker.
CELL SORTING AND HIGH CONTENT ANALYSIS
Investigative toxicology may also fall under the purview of preclinical toxicology departments as a separate unit or as a portion of responsibility. Investigative studies utilizing flow cytometry can be done ex vivo or in vitro to answer relatively simple questions of relative toxicity or mechanism. For example, a multiparameter analysis of oxidative stress could be used as a screening tool for multiple compounds in a drug chemical series to aid in candidate selection for in vivo experiments. Another example is using a calcium flux analysis on cardiomyocytes to determine if the mechanism of cardiotoxicity is due to perturbation of calcium channels. There are many, many ways to apply flow cytometry to investigative toxicology.
All applications described thus far deal only with simple flow cytometric analysis. But there is further potential for application of cell sorting. If, as described, a singlecell suspension can be achieved for analysis by flow cytometry, then cells of interest can be isolated by cell sorting for further experimentation or analysis. Examples of postsort applications include functional assays, cell culture, gene expression analysis, and imaging of enriched cell populations of interest. Cell sorting with subsequent gene expression analysis can be very powerful and provide data unobtainable in any other manner. An example is gene expression analysis of a rare cell population whose transcriptional profile is buried in the "noise" created by more prevalent cell types. Similarly, enrichment of rare target cells for subsequent culture or functional assays provides an opportunity that is nonexistent when these cells are in a heterogeneous mixture. Even if the cells are not rare, isolation of cells of interest eliminates an inherent flaw in gene expression (i.e., mRNA) analysis of mixed populations. This is due to the fact that an increase in the amount of transcript measured, normalized to some housekeeping gene, is universally interpreted as an increase in transcription, often stated as "upregulation," of a gene of interest. But in an uncharacterized heterogeneous population, this could just as likely be due to an increase in percentage of cells expressing the said gene. Assuming all cells in the starting heterogeneous mixture contain roughly equal amounts of mRNA, enrichment of the cell population of interest to just 90% purity is sufficient for providing a valid transcription signature [1] . A case where this assumption is invalid is isolation of reticulocytes or platelets from whole blood where just a few leukocytes per million target cells can greatly skew results since leukocytes contain a two to three orders of magnitude greater amount of mRNA.
Application of flow cytometric analysis in preclinical toxicity studies provides multiple benefits. Multiparameter immunophenotyping of blood or bone marrow, for example, provides a very rich data set compared to simple hematologic analysis. Instead of simply gaining information about the major hematopoietic populations, data on subpopulations, activation states, proliferation, cell cycle, state of maturation, viability, and so on can be obtained simultaneously. High content analysis such as this can provide increased efficiency and cost reduction since a study may require fewer reagents, animals, and time to completion. Presently available instrumentation and fluorescent reporters make multiparameter (10 þ colors) immunophenotyping routine. It is often underappreciated that a single 10-color experiment provides directly correlative data that simply cannot be obtained with two separate five-color panels. In addition, the two-panel approach is inherently inefficient since some antigens are undoubtedly repeated to identify the main populations of interest, hence the savings in resources. There is also the real potential for increased analytical precision. In the case of manual bone marrow analysis, the current "gold standard," it is easy to see how flow cytometry provides increased analytical precision. Basic statistics dictates that the absolute error is larger when counting fewer objects. Manual analysis allows only hundreds of cells to be counted whereas flow cytometry allows from thousands to millions. Flow cytometric cell lineage classification using monoclonal antibodies is also less subjective than manual cytologic methods. A comparison of flow cytometry and manual bone marrow assessment in mice is included in this chapter.
CHALLENGES
Along with the many opportunities come some challenges. Three major challenges are readily identified. The first is antibody availability. Antibodies raised against murine and human antigens, especially hematopoietic cells, are readily available directly conjugated to a plethora of fluorescent reporters. It is more difficult to find directly conjugated antibodies raised against certain rat, dog, and nonhuman primate antigens. In some cases, antihuman antibodies will cross-react; but this is not always true, not even for nonhuman primate (e.g., some anti-CD3 clones). Antibodies for certain antigens/cell types are not available at all. This makes it difficult, if not impossible, to develop identical panels across species. This can be overcome if you have the time and budget to have antibodies developed, else you must wait until the antibodies become commercially available. The second challenge is related specifically to multiparameter, high-content flow cytometry. Assuming antibodies are available for all antigens of interest, it is fairly easy to develop a three-or four-color panel as most antibody vendors provide three or four conjugation choices. FITC, PE, PECy5, PECy7, APC, and APC-Cy7 as well as AlexaFluor variants with similar fluorescence emissions are common choices. And this could be accomplished with one (488 nm) or two laser (488 nm and $640 nm) excitation. But building a 10-color panel can prove a little more difficult. It can be more challenging to identify suitable antibody-fluor combinations and may also require additional lasers for excitation. Furthermore, considerable thought should be given to pairing fluors and antigens. "Brighter" flours should be used to label less prevalent antigens. Consideration should also be given to how spectral overlap (a.k.a. spillover) will affect results. The third major challenge is data analysis. A 10-color analysis will likely provide many unique populations, some of them very rare. The wealth of data provided is extremely valuable but does pose a challenge. Manual analysis using multiple two-parameter dot plots is very cumbersome and requires the person performing the data analysis to identify all populations of interest. Although there have been some interesting attempts at automating portions of data analysis [2] [3] [4] [5] , there is no approach available that is an accepted replacement for a trained cytometrist.
There are also a few lesser challenges that are worth mention. One such challenge is simply getting colleagues in preclinical toxicology to accept flow cytometry-based approaches to analyses that were done using different techniques in the past. Returning to the bone marrow analysis mentioned earlier, where manual evaluation of smears is the commonly accepted practice, it may be difficult to get clinical pathologists and hematologists to endorse a flow cytometric approach. Another challenge could simply be a lack of technical expertise in flow cytometry within the department. An experienced flow cytometrist, especially one with cell-sorter operation experience, is an invaluable asset if flow cytometry is to be a core technique within your organization.
The remainder of this chapter will be devoted to three examples of research performed within the department of safety assessment at a major pharmaceutical company. The first details a multiparameter flow cytometric analysis of oxidative stress for use as an in vitro screening tool. The second involves the search for a biomarker for drug-induced vascular injury and will describe how flow cytometry and cell sorting contributed to this effort. The last example describes the development of a flow cytometric method for bone marrow assessment in mice.
IN VITRO OXIDATIVE STRESS ASSAY
Oxidative stress, characterized by disturbances in cellular redox status, is a frequent mechanism by which drugs and chemicals induce toxicity [6] . Therefore, measurement of drug-induced oxidative stress in vitro can be useful in assessing toxicity of potential drug candidates. Flow cytometry is the perfect choice for this application since it provides simultaneous data acquisition from multiple parameters allowing analysis of diverse functional changes on an individual cell basis [7] . In addition, a wide variety of fluorescent probes are available for studying pathophysiological changes in cells associated with drug toxicity. The objective of this study was to develop a multiparameter flow cytometric method to assess oxidative stress induction in cultured cells by simultaneously measuring relative intracellular glutathione level, mitochondrial membrane potential, lipid peroxidation, apoptosis, and plasma membrane integrity using fluorescent reporters for these end points.
6.5.1 Methods 6.5.1.1 Cell Lines and Maintenance The promyelocytic leukemic cell line HL-60 was employed as it is commonly used for in vitro toxicity assays within the department. HL-60 cells obtained from American Type Culture Collection (ATCC, Gaithersburg, MD), were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 I.U. penicillin, and 100 mg/ml streptomycin at a density of 1 Â 10 6 cells/mL in T150 culture flasks at 37 C in a 5% CO 2 humidified atmosphere. Cells were harvested the day before a planned experiment and replated at a density of 5 Â 10 5 cells/mL. Table 6 .1 defines the model toxicants and remedies evaluated (end point, vehicle, concentrations, and known remedy conditions). Table 6 .2 provides information on the fluorescent reporters used (end point, interpretation, concentration, and excitation, and filter collection wavelength information). culture and an aliquot counted on a hemacytometer to determine cell number and assess viability using trypan blue. An appropriate volume of cell suspension was placed in a 50 mL conical tube and centrifuged at 200 g for 5 min at room temperature (RT). Cells were suspended in a like volume of HBSS and centrifuged again. Cells for single-color flow cytometry compensation controls were removed, treated, and stained separately. TMRM (30 mL of 500 nM in HBSS) was added to cell pellet and vortexed followed by incubation for approximately 15 min at 37 C. Cells were centrifuged as before, resuspended in 30 mL of 5-DAAF (100 nM in HBSS), vortexed, and then incubated for approximately 60 min at 37 C. Sample was removed from incubator, aliquoted among appropriate number of 12 Â 75 mm polystyrene tubes, and then centrifuged as before. In some cases, cells were then preincubated with compound appropriate to alleviate the effect of the toxicant to be tested, which will be denoted as remedy compounds. Four toxicant/remedy compound pairs were tested: menadione/NAC, hydrogen peroxide/catalase, FCCP/cyclosporin A, and paclitaxel/ Z-VAD-FMK. Cell pellets were suspended in 500 mL of the appropriate remedy compound or HBSS and incubated for approximately 60 min at 37 C. Treatments were added at a 2Â concentration and vortexed before proceeding with no centrifugation. Cells were incubated for approximately 30, 60, or 120 min at 37 C and then centrifuged as before. Supernatants were removed and cells were resuspended in 100 mL Annexin V staining solution containing AnV-APC. Samples were incubated at RT in the dark for 15 min, then 500 mL of HBSS containing mBCl and ASBMS was added to each tube and vortexed. After 10 min of incubation at RT, cells were immediately analyzed by flow cytometry (Figure 6 .1). Triplicate samples were run for each experiment and an experiment for each compound was run on three separate days.
Test Articles and Reporters

Flow Cytometry
The five fluorescent signals (TMRM, 5-DAAF, mBCl, ASBMS, and Annexin V-APC) were collected as outlined in Table 6 .2. A minimum of 10,000 events was collected per sample. Median fluorescence intensity (MFI) was recorded for 5-DAAF, TMRM, and mBCl as a measure of lipid peroxidation, mitochondrial membrane potential, and intracellular glutathione content, respectively. Apoptotic cells were enumerated by determining the percentage of events that displayed phosphatidyl serine exposure, yet did not have compromised plasma membranes as determined by positive staining for AnV-APC and dim/ negative staining for ASBMS (AnV þ /ASBMS À ). Cells with compromised plasma membranes were considered dead/necrotic and were enumerated by determining the percentage of events that stained brightly for ASBMS (ASBMS þ ).
Results and Discussion
Vehicle Effects
Vehicle (0.1% DMSO) had a protective effect on relative intracellular glutathione content that increased in magnitude over time. Measured mBCl fluorescence increased to 56.41 AE 9.62 of untreated control at 120 min.
No appreciable effect was seen on lipid peroxidation (5-DAAF) or mitochondrial membrane potential (TMRM). Absolute values of both incidence of apoptosis and cell death in vehicle-treated samples and trends of increased incidence over time were similar to those observed in untreated samples.
Time Effects
All 12 experiments contained untreated control samples. In order to determine effects of time alone, the average change from the 30 min time point was calculated for the 60 and 120 min time points for relative glutathione content, lipid peroxidation, and mitochondrial membrane potential parameters. Relative glutathione content measurement was shown to be very sensitive to time with significant variance from 30 min values at 60 and 120 min. Mean percentage change in mBCl fluorescence from 30 min time point was À40.0 AE 10.1 and À73.8 AE 5.1 at 60 min and 120 min, respectively. Lipid peroxidation and mitochondrial membrane potential measurements were less sensitive over time, but still varied appreciably at 120 min and at 60 and 120 min, respectively.
Incidence of apoptosis and cell death both increased slightly over time. Incidence of apoptosis and cell death of less than 5% was considered inconsequential; therefore, only the incidence of cell death at 120 min (9.4 AE 2.3 %) was considered a biologically relevant time-induced stress result. These effects were similar to those seen in cells treated with 0.1% DMSO and therefore were interpreted as time-induced stress effects with little vehicle effect observed.
Data Analysis
Due to the nature of mechanism of action of the fluorescent reporters 5-DAAF, mBCL, and TMRM, a large interexperimental variation was observed. Therefore, all MFI (median fluorescence) data were normalized as a percentage change from vehicle control and/or percentage change from untreated for comparison of trends among like experiments run on separate days. No normalization of apoptosis and necrosis data was needed since absolute values of percent apoptotic and necrotic can be compared directly. Percentage change from vehicle control and untreated may still be computed easily but is of limited utility. While percentage change analysis may allow a better visualization of trends due to the fact that small absolute changes may translate to fairly large percentage changes, this may also overemphasize a change that is not biologically relevant. For example, an apoptotic index of 2% in treated versus 1% in control is a 100 percent change from control (increase), but reporting this as such misleadingly implies great biological significance. Therefore, it is suggested that only absolute percentages are analyzed and presented for apoptosis and cell death parameters.
Test Pair 1: Menadione and NAC Menadione consistently produced a concentrationand time-dependent decrease in relative intracellular glutathione level, the primary target parameter for this tool compound. Mean percentage change in mBCl fluorescence from control was À84.1 AE 3.5, À89.3 AE 2.9, and À97.7 AE 5.0 at 30, 60 and 120 min, respectively, in cells treated with 100 mM menadione. Lipid peroxidation was evident at 120 min with all concentrations, but inconsistent across experiments. Decreased mitochondrial membrane potential was observed at 30 min with 100 mM; at 60 min with 30 and 100 mM; and at 120 min with 10, 30, and 100 mM. The magnitude of the decrease at 120 min was similar for 10 and 30 mM. A slight increase in mitochondrial membrane potential over untreated control was seen at 60 min with 10 mM similar in magnitude to that seen in the vehicle control. There was no effect on apoptosis. An appreciable increase in cell death was observed with 100 mM at 120 min. NAC greatly abrogated the effects of 100 mM menadione on relative glutathione content. NAC-treated cells lost only 12.7% of mBCl fluorescence at 120 min compared to 97.7 % in cells that did not receive NAC. NAC also greatly reduced the amount of menadione-induced cell death and completely abrogated effects on lipid peroxidation and mitochondrial membrane potential. In fact, measured TMRM and 5-DAAF fluorescences were at levels above untreated.
Test Pair 2: FCCP and Cyclosporin A FCCP consistently produced a concentrationdependent decrease in mitochondrial membrane potential, the primary target for this tool compound. This effect was observed at all time points, but the best separation in effect was at 30 min due to the fact that mitochondrial membrane potential decreased over time in the absence of compound treatment. FCCP effects on relative intracellular glutathione content varied depending on concentration and time, but in all cases values were above untreated controls at the corresponding time point. The greatest difference between treated and control was seen at 60 min. FCCP at all concentrations slightly increased 5-DAAF fluorescence, interpreted as decreased lipid peroxidation, at 60 and 120 min with a peak seen at 60 min. A very slight increase in cell death was observed at all time points with all concentrations. However, even vehicle controls demonstrated relatively high levels of cell death in comparison to vehicle control groups in other compounds. Cyclosporin A did little to prevent mitochondrial depolarization by FCCP in the current study. Oligomycin may be superior in this regard and is recommended as a possible substitute [8] . Cyclosporin A pretreatment resulted in further elevation of relative intracellular glutathione above untreated control. Lipid peroxidation was also further reduced, as determined by 5-DAAF fluorescence values above those of untreated control on average, but with a very large variation. There was no effect on cell death.
Test Pair 3: Hydrogen Peroxide and Catalase A concentration-dependent increase in lipid peroxidation, the primary target for this tool compound, as determined by a decrease in 5-DAAF fluorescence intensity, was observed at all time points with the best separation at 120 min. Hydrogen peroxide caused an increase in relative intracellular glutathione that increased in magnitude over time. A slight increase in mitochondrial membrane potential was observed with 100 mM at 30 min and 10 mM at 120 min. Slight and dramatic decreases in mitochondrial membrane potential were observed at 120 min at concentrations of 30 and 100 mM, respectively. Cell death increased moderately over time in samples treated with 100 mM.
Catalase pretreatment only slightly abrogated hydrogen peroxide-induced lipid peroxidation. Catalase had no additional effect on relative intracellular glutathione content. Reduction of mitochondrial membrane potential was partially negated. Incidence of cell death was decreased slightly.
Test Pair 4: Paclitaxel and Z-VAD-FMK
A concentration-dependent increase in apoptosis, the primary end point for this tool compound, was observed at all time points although no concentration yielded an increase in percent apoptotic over time. Paclitaxel increased mean relative intracellular glutathione at 60 min in a concentration-dependent manner, but with a great variation in magnitude of response at 100 mM. Lipid peroxidation was slightly lower (higher 5-DAAF MFI) at 120 min at concentrations of 10 and 30 mM. Mitochondrial membrane potential was reduced at all time points by 100 mM paclitaxel. A concentration-dependent decrease was observed at 120 min. Cell death was slightly elevated at all time points with a concentration-dependent effect observed at 60 min, but of biologic significance only at 120 min.
Z-VAD-FMK did not appreciably reduce the incidence of apoptosis. Addition of Z-VAD-FMK increased mean relative intracellular glutathione content more than paclitaxel alone. Z-VAD-FMK had no effect on lipid peroxidation, mitochondrial membrane potential, or cell death parameters.
Z-VAD-FMK worked poorly as an inhibitor of paclitaxel-induced apoptosis when used as described in this study. Recent literature reports that inhibitors of caspase-3, -6, or -8 partially reduce paclitaxel-induced apoptosis but caspase-10 inhibition totally abrogates the process [9] . Z-VAD-FMK was chosen for this study since it is purported to be a pan-caspase inhibitor, but in hindsight it appears that a caspase-10-specific inhibitor, such as Z-AEVD-FMK, may better attenuate the effect of paclitaxel [10] . Z-AEVD-FMK or a combination of Z-AEVD-FMK and Z-VAD-FMK as well as a higher concentration of inhibitor (100 mM) is suggested.
Assay Design Observations
The simultaneous use of ASBMS and mBCl requires significant fluorescence compensation due to a large amount of spectral overlap. Proper compensation using appropriate single-color controls is paramount to achieve accurate fluorescence measurements for mBCl. Multiple titration experiments were performed to determine working concentrations of TMRM, 5-DAAF, and all tool compounds, as well as time points of interest that were appropriate for HL-60 cells cultured as described. Changes in culture conditions of HL-60 cells, the use of a different cell line, and/or the use of primary cells would likely require similar titrations to optimize experimental conditions to achieve desired effects from tool compounds. If using to screen compounds of unknown mechanism of toxicity, a wider range of concentrations may be needed to appreciate toxic effects. This assay as described for use with HL-60 cells is suitable only for short-term experiments due to the great stress effects observed over time, even in untreated cells. In addition, it is conceivable that at least some loss of signal of mBCl, 5-DAAF, and TMRM at later time points is due to leaching of respective fluorescent reporters from cells and not due to an actual decrease in intracellular glutathione, increase in lipid peroxidation, and decrease in mitochondrial membrane potential. Therefore, time points of 15, 30, 45, and 60 min are recommended for future studies with HL-60 cells. It is recommended that tool compounds, such as those described herein, be included as positive controls in all experiments applying this assay. Also, due to variation observed with tool compound treatments, multiple samples should be run simultaneously in each experiment and then results from multiple experiments compared to confirm results. This is deemed especially important if investigating toxicants with unknown modes of action and/or toxicants that may not produce the magnitude of change seen with positive control tool compounds.
Concentration-dependent changes in relative intracellular glutathione content (decrease), lipid peroxidation (increase), mitochondrial membrane potential (decrease), and apoptosis (increase) were induced with the tool compounds menadione, hydrogen peroxide, FCCP, and paclitaxel, respectively, in HL-60 cells. In addition, secondary effects on other stress parameters, both negative and positive, were also observed, suggesting cross talk among parameters and/or propagation of the stress effect to other compartments. This strongly supports the use of multiparameter analysis during assessment of cytotoxicity, especially if mechanism is a goal of the experimental design. Effects of time and vehicle (0.1% DMSO) were also observed and should be considered when performing experiments of this type. Multiparameter flow cytometry is deemed valid for reporting the effects of known toxicants on oxidative stress, apoptosis, and cell death parameters simultaneously in HL-60 cells. This method could be applied as a screening tool to investigate the multistress potential and mechanism of toxicity of uncharacterized toxicants on HL-60 cells.
DEVELOPING A BIOMARKER-BASED ASSAY FOR DRUG-INDUCED VASCULAR DAMAGE
A robust blood-based preclinical toxicity assay requiring only phlebotomy for sample collection that predicts or corresponds to histopathological findings of vascular injury is highly desirable. In 2005, the Expert Working Group on Drug-Induced Vascular Injury, composed of toxicologists and pathologists from the pharmaceutical industry, academia, and the Food and Drug Administration (FDA), stated that "aside from histological methods, the detection, noninvasively, of acute drug-induced vascular injury in animals or humans is not possible due to the lack of specific and sensitive biomarkers of endothelial and/or vascular smooth muscle injury" [11] and this remains the case as of this writing. Historically, vascular injury was monitored by looking for changes in blood pressure (BP) and/or heart rate (HR) as vascular damage was not observed without concomitant changes in these parameters. It was discovered that some newer drug classes could cause vascular injury in animals without measurable changes in BP or HR. Some examples are endothelin-receptor antagonists, dopamine (DA1) agonists, adenosine agonists, and later generation phosphodiesterase 4 inhibitors. This problem is compounded by the relatively low therapeutic index for some of these drugs. There is also a trend toward increasing frequency of histological vascular lesions in preclinical toxicity studies and increasing pressure from regulatory agencies (FDA and others) to identify reliable biomarkers. Given this, a large multiyear effort consisting of many individual studies and multiple species was undertaken with the task of developing a specific, sensitive, noninvasive method for detection of drug-induced vascular injury that predicts or correlates with histopathology in multiple animal species used in preclinical toxicity studies with a potential for adaptation to a clinical setting.
Endothelial Model
A large portion of this effort was given to enumeration of circulating endothelial cells (CECs) and/or circulating endothelial progenitors (CEPs) from rat blood (control and tool compound treated), sorting of cell populations of interest, and subsequent gene expression analysis (i.e., genechip, PCR, etc.). A rat model was chosen since it is commonly used in preclinical drug development toxicity testing. Familiarity within the department with existing drugs that induce mesenteric vasculopathy in rats was also useful in providing tool compounds for method development and proof-ofconcept experiments.
CECs were first described decades ago as a possible indicator of drug-induced vascular damage [12, 13] , but few publications correlating CECs and drug-induced injury exist. However, there have since been numerous publications describing correlations between CEC numbers and various human disease states, and CEC enumeration is gaining acceptance as a clinical biomarker of vascular disease [14] . Unfortunately, there is no consensus method for enumeration or immunophenotypic definition of human CEC/CEP [15] . In addition, very few publications exist on flow cytometry and CEC/CEP in animals. Lack of consensus methods made the undertaking particularly challenging since so many factors can impact results including euthanasia (e.g., CO 2 , isofluorane, etc.), blood collection method (e.g., blood vessel, needle size, and anticoagulant), blood fraction processed (e.g., lysed whole blood, mononuclear fraction, and platelet-rich plasma), enumeration method (e.g., microscopy after centrifugation, microscopy after magnetic enrichment, and flow cytometry), and primary phenotypic identifier (e.g., cellular morphology alone, DiI-Ac-LDL uptake, lectin binding, and various cell surface proteins). Lack of consensus methods also made it difficult to establish a "normal" range for basal CEC levels since basal levels in humans greatly vary among methods employed [15] . Rat CEC gene expression was also unprecedented although microarray analysis had been done with magnetically isolated human CEC [16] .
Identifying CEC/CEP Markers
Initial experiments in untreated animals used 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine perchlorate-acetylated low-density lipoprotein (DiI-Ac-LDL) that has been widely used as endothelial identifier. DiI-Ac-LDL has been used by other investigators in sorting experiments to isolate endothelial cells from explant cultures [17, 18] . This reagent was useful for early method development work but was logistically impractical for biomarker development and cell sorting with subsequent gene expression analysis experiments since it requires a 4 h incubation period to allow uptake. Since DiI-Ac-LDL is ingested through binding to scavenger receptors, it was postulated that a similar cell population could be identified using an antibody against said scavenger receptor. CD36 is a type B scavenger receptor and the rat ortholog, fatty acid translocase (FAT), has been shown to be present on endothelium [19] . Rat blood samples costained with DiI-Ac-LDL and anti-CD36 exhibited $80% overlap between labels, therefore anti-CD36 antibody replaced DiI-Ac-LDL in all subsequent experiments. However, CD36/scavenger receptor is also present on the cell surface of other cell types in circulation including macrophage/monocytes, erythrocytes, and platelets. Initially, only monocytic lineage cells were excluded using anti-CD11b/c since ammonium chloride lysis of RBCs was performed and platelets are easily excluded based on size. In hindsight, given the sheer number of erythrocytes in blood, the fact that lysis is not 100% effective, reticulocyte resistance to lysis and very low number of CECs, it should also have been obvious that erythrocyte lineage would comprise a large percentage of remaining CD11b/c À /CD36 þ cells. Negatively selecting for erythrocyte lineage was problematic because the only antirat erythroid antibody available at the time was an IgM isotype. This reagent led to agglutination and severe clump formation. To circumvent this problem, the cell-permeant DNA binding dye Hoechst 33342 (HO) was used to identify nucleated cells allowing negative selection of both erythroid lineage and (free) platelets. Since it was confirmed that platelets often associated with other cell types, it became necessary to add anti-CD42d to exclude platelet-associated cells from analysis [20] . Anti-CD3 and anti-CD45R were included to negatively select for T and B lymphocytes, respectively. A specific reagent to negatively select for NK cells was not necessary as they are CD11b/c þ in the rat strain (Sprague-Dawley) used. Although some DEVELOPING A BIOMARKER-BASED ASSAY FOR DRUG-INDUCED investigators choose to use a pan-leukocyte marker (i.e., CD45) rather than a panel for leukocyte subsets, this is not recommended since there is disagreement in the literature regarding CD45 status on progenitors (hematopoietic and endothelial). Our department was also privy to unpublished observations from another laboratory that observed CD45 þ immunohistologic staining of endothelium of select vascular beds. Therefore, the minimum immunophenotypic definition used to identify putative CEC/CEP became CD36
À /ASBMS À . CD3, CD11b/c, CD45R, and CD42d were combined into a single-color hematopoietic lineage "dump" channel to allow room for other endothelial "specific" antibodies. CD36 þ /Lin À will be used for brevity throughout the rest of this chapter to refer to the minimum immunophenotype. Representative flow cytometry data and sorting strategy is described in Figures 6.2 and 6 .3. Other antigens investigated for CEC/CEP identification included CD31 (PECAM-1), CD54 (ICAM-1), CD105 (endoglin), CD106 (VCAM-1), CD133 (AC133), CD144 (VE-Cadherin), CD146 (MCAM), rat endothelial cell antigen (RECA)-1, vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, and von Willebrand factor (vWF). It is worth mentioning that CD146 is the most widely used primary identifier in human CEC publications. Contrary to claims in early publications, CD146 expression is not specific to CEC but is found on some leukocyte subsets (e.g., activated T-cells) [15] and therefore negative selection of leukocytes is still necessary. It was hoped that some of these antigens (e.g., CD133) might be useful to distinguish CEC from CEP and provide information about activation status (e.g., CD144), but results were equivocal. Within the CD36 þ /Lin À population, very few cells were positive for any of the other antigens examined, , and CDH5 (VE-Cadherin, CD144). Gene expression paralleled flow cytometry results in that not all "endothelial-specific" genes were present and differential expression was observed across animals (control only). Only EDN1 was consistently expressed in sorted CEC/CEP fractions. Utility of probes was confirmed using rat heart homogenate. This supported the hypothesis of a complex mixture of cell types within the CD36 þ /DiI-Ac-LDL þ population. As with protein expression, heterogeneity in gene expression in endothelium has been reported and attributed to differences in functional or differentiation status that, in some cases, can be modulated by drug treatment [22, 23] . Heterogeneity in gene expression patterns has also been demonstrated across endothelial subtypes from distinct regions of the heart [24] [25] [26] .
In addition to confirmatory gene expression experiments, cell culture of normal rat PBMC and sorted CD36
þ Lin À and DiI-Ac-LDL þ /Lin À cells was performed. First, a modified human colony forming unit (CFU)-Hill assay [27] using rat PBMC was successfully employed to confirm existence of CEP. Longer term culture resulted in disappearance of colonies and emergence of spindle-shaped cells that stained positively for CD31, von Willebrand factor, and rat endothelial antigen (RECA)-1 and negatively for smooth muscle a-actin (SMA), an immunophenotype consistent with mature endothelial cells. CFU-Hill assay confirmed existence of CEP in normal rat blood but required ProNectinF, as opposed to traditional fibronectin, as substrate [28] . The CFU-Hill assay begins with PBMC that are plated for 2 days, then nonadherent cells are removed and replated for the actual colony-forming assessment. This nonadherent fraction was examined by flow cytometry to confirm existence of CD36 þ /Lin À cells. In addition, sorted CD36 þ /Lin À cells were placed in culture directly, treating them as "nonadherent PBMC." Although colonies formed as with PBMC, longer term culture did not produce outgrowth of endothelial-like cells. This was likely due to the absence of other cell types that are necessary for outgrowth in culture. Monocytes and T cells have both been implicated as necessary for endothelial maturation and/or vascularization [29, 30] .
Drug Toxicity Experiment
All experiments up to this point were performed in-house using freshly prepared lysed whole blood samples from just a few rats at a time. But the in-life portion of definitive studies, including dosing with tool compounds, were to be performed at remote locations. Each experiment consisted of four (vehicle control, low-, mid-, and high-) dose groups with six rats per group. This required that samples be fixed and/or frozen to survive transport and short-term storage (only a few rat samples could be sorted per day). In initial experiments, paraformaldehyde (PFA) fixation proved incompatible with mRNA analysis, so an alternative preservation method was sought that provided satisfactory flow cytometry results and sufficient amount of recoverable mRNA. In addition, all fixatives and buffers were made with DEPC-treated water. All vessels that came into contact with samples were rinsed with DEPC-treated water before use. The cell sorter was decontaminated with bleach and rinsed with DEPC-treated water before each sort. RNA integrity/yield was compared among sorted and unsorted leukocytes isolated from fresh lysed whole blood and preservation methods under consideration included PFA (4% and 0.2%, repeated with DEPC-treated water formulation), RNAlaterÔ, Cyto-Chex Ò , "RNA-friendly" fixative (formalin/EtOH/ AmOH), formaldehyde/MetOH, 90% EtOH, 90% MeOH, EtOH/acetone, and freshfrozen in RPMI-10% DMSO. Further attempts to improve integrity included adding RNAsecureÔ to PFA, formulating with chloride/citrate buffer instead of PBS, and trial of different commercially available RNA isolation and extraction kits (two each). In the end, only fresh-frozen samples gave both satisfactory flow cytometry and RNA integrity results. Samples could be stored up to 7 months without appreciable impact on immunophenotyping results. There was a slight reduction in RNA integrity/yield after four weeks.
For definitive studies, global gene expression profiling of CD36 þ /Lin À cells by microarray was performed. The goals of this effort were to identify potential protein targets useful for more robust immunophenotypic characterization and to provide information on vascular injury pathogenesis in rats dosed with known vascular toxicants. Doses were chosen based on previous experience and/or literature review. One such study is outlined as follows.
6.6.5 Methods 6.6.5.1 Dosing/Sample Collections Male Sprague-Dawley rats (350-500 g; 6 per dose group) were given vehicle (sterile water), 1, 3, or 10 mg/kg/day serotonin (5HT) subcutaneously (2 mL/kg) for 4 days and blood was collected terminally approximately 24 h after the last dose. Postnecropsy pathologic examination of mesenteric rolls with lesion scoring and statistical analysis confirmed induction of dose-dependent mesenteric arterial vascular injury using this study design.
DEVELOPING A BIOMARKER-BASED ASSAY FOR DRUG-INDUCED
After carbon dioxide asphyxiation, rats were exsanguinated via the caudal vena cava by collecting blood (approximately 10 mL per rat) into a 10 mL syringe with an 18 gauge needle containing 200 mL of 10% w/v disodium EDTA. Blood was processed immediately; else syringes were rocked at room temperature until processed (<15 min). EDTA-anticoagulated blood was aliquoted, sans needle, into 50 mL conical tubes in 5 mL volumes. Ice-cold ammonium chloride RBC lysis buffer (40 mL/tube) was added and tubes were inverted gently several times to mix. Samples were incubated at RT for approximately 20 min to allow lysis of RBCs, centrifuged at 200 g for 5 min at RT, and supernatants removed, then washed with 20 mL PBS. Pellet was resuspended in 5 mL of 10% DMSO-RPMI, vortexed, and samples were aliquoted (1 mL) into 4.5 mL cryovials and placed on dry ice for transport. Upon arrival (same day) samples were transferred to freezer (À80 C) for storage (up to 7 days).
Enrichment and Cytometry. Cryovials were removed from freezer and thawed in 37 C water bath. PBS (2 ml) was added to each vial and vortexed. Replicate sample vials were combined and washed with PBS before addition of antibody cocktail containing CD3-, CD45R-, CD42d-, and CD11b/c-(Lin)-FITC and CD36-PE. Cells were incubated on ice in the dark for 20 min, washed again, and then resuspended in 2 mg/mL HO in AutoMACS running buffer (AB, 400 mL). Anti-PE microbeads (200 mL) were added to each sample and incubated at 4 C for 15 min with gentle tilting on Speci-Mix. AB (9.4 mL) was added (10 mL total volume) and samples were centrifuged at 300 g for 10 min at 4 C. Supernatants were removed and pellets resuspended in 500 mL AB and then separated using the POSSELDS AutoMACS program for positive selection of rare events. Positive (CD36 þ enriched) and negative (lineage) fractions were both collected into 12 Â 75 mm polystyrene tubes and processed for cell sorting. Collected fractions were centrifuged at 200 g for 5 min at 4 C. CD36 þ enriched fraction was resuspended in 200 mL volume and lineage fraction was resuspended in 1 mL volume of PBS w/1% BSA and placed on wet ice until cell sorting. CD36 þ /Lin À /HO þ cells were sorted and reanalyzed to assess purity (always ! 90%) and then processed for RNA isolation.
6.6.5.2 GeneChip Analysis Appropriate volume of RNA lysis buffer was added to sort sample and contents transferred to 1.5 mL microfuge tube and vortexed vigorously. Samples were freeze-thawed twice by placing them on dry ice followed by 37 C water bath and then stored at À80 C until RNA isolation using Absolutely RNA Microprep Kit (Stratagene). Samples were concentrated using RNA Clean-up Kit-5 (Zymo Research). Total RNA from each concentrate was quantified using a modified version of RiboGreen RNA Quantification Kit Low Range Assay (Molecular Probes). Quality was assessed by the presence of 18S and 28S ribosomal bands using Agilent 2100 Bioanalyzer and RNA Pico LabChip Kit (Agilent). RNA samples were stored at À80 C until GeneChip analysis. All samples were randomized into two groups and assigned to two separate scientists for amplification along with one rat liver RNA, serving as a technical control, per group. All samples were amplified and biotin-labeled using the NuGEN OvationÔ Biotin System. Size and integrity of amplified cDNA (SPIA) products and fragmented and biotin-labeled SPIA product were assessed using the Agilent 2100 BioAnalyzer RNA 6000 Nano LabChip Ò system. Fragmented and biotin-labeled SPIA yields and purities were determined by measuring O.D.260, O.D.280, and O.D.320 using NanoDrop. Targets containing 2.2 mg of fragmented and biotin-labeled SPIA were prepared for hybridization onto the Affymetrix GeneChip Rat Genome 230 þ 2.0 arrays. Samples were hybridized for approximately 18 h at 45 C in a hybridization oven at 60 rpm rotation. Following hybridization, arrays were washed and stained with R-phycoerythrin streptavidin using the Affymetrix EukGEWS2v4_450_OneFill protocol. Arrays were scanned using a GeneChip Ò Scanner 3000. Array quality was analyzed by principal component analysis; results indicated zero outliers due to overall array quality.
Results and Discussion
Statistical evaluation of linear dose response was used to identify toxicologically relevant genes, that is, genes whose expression changed linearly with increasing dose and hence increasing severity of vascular injury. For each gene, dose response was evaluated by application of a statistical trend test to expression values to obtain a P-value for linear response to increasing dose. Specifically, a one-way ANOVA analysis across dose groupings was followed by calculation of a t-statistic using a post hoc contrast for linear trend. A gene-specific reference distribution for the observed t-statistic was obtained using 100,000 permutations of the dose labels and recalculating the t-statistic for each permutation. A P-value for dose response was then obtained by comparing the observed t-statistic against the reference distribution. Over 1602 statistically significant dose-responsive genes were identified (P < 0.01). This is above the number expected by chance based on a chip of this size (31,099 genes). Representative data from four genes of interest is presented in Figure 6 .4. These results demonstrated that gene expression analysis of sorted CECs in preclinical vascular toxicity studies is feasible. Many other tool compounds were investigated using a similar study design providing a wealth of data that is still being explored.
MOUSE BONE MARROW ASSESSMENT
Bone marrow differentials in preclinical toxicology studies are routinely assessed by manual microscopic evaluation. This method is tedious and labor intensive, with several hundred cells being counted per slide. Evidence suggests that flow cytometric analysis of rodent bone marrow can identify major hematopoietic subsets and reveal hematologic abnormalities [31] [32] [33] [34] . Therefore, flow cytometric bone marrow differential analysis was investigated as a replacement to the manual cytologic technique. To this end, a multiparameter flow cytometric panel consisting of antibodies against erythroid (ter119), leukocyte (CD45), and myeloid (CD11b) antigens and the DNA binding dyes Hoechst 33342 (HO) and 7-aminoactinomycin D (7AAD) was devised to identify viable nucleated cells of erythroid, myeloid, and lymphoid lineages for comparison with manual cytologic analysis of mouse bone marrow.
Methods
Sample Collection
Mice were killed by carbon dioxide asphyxiation and exsanguination. Both femurs were removed and dissected free of soft tissues. Right femurs were used for flow cytometric analysis and cytospin preparations and left femurs for bone marrow smear preparation. Previous experiments confirmed no statistically significant difference in bone marrow differentials among femurs in same animals.
6.7.1.2 Cytology Bone marrow smears were prepared using standard methods. Cytospin slides were prepared from collected whole bone marrow and sorted cells. Cells (2 Â 10 5 ) were washed and resuspended in 250 mL PBS. Cytospins were prepared using PolysineÔ-coated slides (Erie Scientific Company, Portsmouth, NH) on a cytospin 2 (Shandon, Inc., Pittsburg, PA) and then fixed and stained using an Advia S60 automated slide-staining system (Bayer, Tarrytown, NY). Cells were visualized with a Nikon Eclipse E-800 microscope (Nikon, New York) using a Plan Apo100X oil objective (Nikon) and photomicrographs were taken with a Spot RT Slider digital camera (Diagnostic Instruments, Inc., Sterling Heights, MI). Images were prepared with Photoshop (Adobe Systems, San Jose, CA).
6.7.1.3 Flow Cytometry Myeloid, lymphoid, and nucleated erythroid populations were positively identified using fluorochrome-conjugated monoclonal antibodies. Antibody cocktail consisted of antimouse CD45-APCCy7, ter119-PE, and CD11b-APC. HO (2 mg/ml) and 7AAD (1 mg/ml) were used for nuclear recognition and dead cell exclusion, respectively. First, 7AAD staining was performed (10 min, RT) and then samples were washed, fixed (1 % PFA), and stored refrigerated overnight. Smears and cytospins were evaluated and scored by an experienced hematology technologist.
In order to confirm that manual cytologic characterization was in agreement with flow cytometric immunophenotype for the major lineage populations, nucleated erythroid, myeloid, and lymphoid lineage cells were sorted and reanalyzed to assess purity and cytospins were prepared for cytologic evaluation. 
þ /CD45 þ double-positive, and ter119 À /CD45 À double-negative events were excluded as dead, aggregates, and debris, respectively. Sorting experiments revealed that flow cytometric identification of nucleated erythroid, lymphoid, and myeloid bone marrow subsets agreed very well with manual cytologic classification. The cell type sorted agreed with cytologic characterization in all cases and variation in stated purity of sorted populations by flow cytometric reanalysis versus cytologic assessment of cytospins was less than 3% for all populations.
In an effort to further investigate the utility of flow cytometric bone marrow analysis in toxicology studies, recombinant human erythropoietin (rhEpo) was used as a tool compound and administered to mice. A single subcutaneous injection of rhEpo at a dose of 3000 U/kg is sufficient to stimulate erythroblast production in mouse bone marrow with maximal effect observed 48 h postdose [35] . Therefore, bone marrow was collected approximately 48 h after a single injection. A dose of 1000 U/kg was included to investigate dose-response relationships. The effects on mouse bone marrow populations were monitored by flow cytometric analysis and cytologic assessment of bone marrow smears and results were compared.
Results and Discussion
A comparison of flow cytometry and cytology results produced similar trends in all monitored end points. Both methods revealed dose-responsive changes in bone marrow, although more instances of statistical significance were observed in flow cytometry data. This can be attributed to lower intragroup variation present in flow cytometry results versus cytology that is not surprising given that a much larger number of cells are interrogated in flow cytometric analysis. A comparison of methods using least square means was used to statistically confirm this assertion (Figure 6 .5). Results strongly suggest greater sensitivity of flow cytometric methodologies to identify drug-induced bone marrow changes as demonstrated by dose-dependent changes seen in nucleated erythroid and lymphoid compartments on a percentage basis, nucleated erythroid on an absolute basis, and M:E (myeloid: erythroid) ratio whereas no dose-dependent changes of statistical significance were observed by cytology.
A trend for flow cytometric erythroid enumeration values to be below those determined cytologically was observed (Figure 6 .6). Although this discrepancy in erythroid enumeration appeared striking at first glance, paired t-test comparison of methods revealed statistically significant difference among methods only in absolute erythroid in the 1000 U/kg dose group. M:E ratio is a commonly used bone marrow assessment. Repeated measure analysis of variance (ANOVA) modeling of M:E ratios actually revealed very good correlation (R ¼ 0.99) among methods (Figure 6.7) . Regardless, this discrepancy of absolute values was of some concern.
A definite advantage of flow cytometry over manual cytologic assessment of bone marrow cells is less ambiguity in determination of cell types as monoclonal antibodies are employed allowing both positive and negative selection. For example, in order to be characterized as a lymphocyte a cell must stain positively for CD45 but negatively for both CD11b and ter119. There is little chance for investigator bias to negatively impact cell determination on a cell-by-cell basis, whereas manual cytologic determination is based solely on a single medical technologists judgment for each individual cell. In addition, flow cytometry has the advantage of decreased absolute counting errors due to the large number of cells interrogated (at least 10,000) versus only 100-500 for manual methods. Therefore, a case could easily be made as to why the flow cytometry results would be more accurate and reliable. However, the reality is that manual cytologic assessment is the "Gold Standard" and the incongruence observed simply cannot be dismissed. Possible explanations for this incongruence, other than stating that one method is right and the other one is wrong, do exist. The first is that manual and flow cytometric analyses were not performed on identical samples. Flow cytometric analysis was performed on suspensions of bone marrow cells from the left femur and cytology was performed on a smear created from the right femur. However, previous experiments did not reveal significant differences between femurs. Instead, differences may be attributed to the fact that smears are created from a small portion of the total femoral bone marrow, whereas flow cytometric preparation homogenizes the entire femoral bone marrow population, precluding potential sampling errors. A second possible explanation for lack of parity is the fact that some events are excluded from analysis during flow cytometric assessment. This is necessitated by the existence of minor populations of cell aggregates and nonstaining cells. Although the nonstaining population does not stain positively for any of the monoclonal antibodies used, it does stain with the nuclear dye, Hoechst 33342. This staining pattern argues that the events are not hematopoietic lineage cells and should, in fact, be excluded from analysis. The identity of these events could be primitive stem cells that do not yet express lineage markers, other resident bone marrow cell types (e.g., osteoblasts, osteoclasts, and osteocytes), or perhaps free nuclei. It is tempting to speculate that these events are free nuclei of erythroid cells that were in the process of nuclear extrusion upon harvest, but there is no direct evidence of this at present. In addition, there is a small percentage of coincident or aggregate events that also must be excluded in analysis of flow cytometry samples, but this seems unlikely to negatively impact the overall differential as cells excluded as aggregates are preferentially not one cell type. It should be noted that the exclusion of cell aggregates is a common practice in flow cytometric analysis and is performed to assure that data are from individual cells.
The possibility that preparation of mouse bone marrow samples for flow cytometric analysis leads to preferential removal and/or destruction of erythroid cells is another possibility that cannot be discounted. In order to have full confidence in flow cytometric results from mouse bone marrow, the lack of parity between flow cytometry and manual cytology would need to be resolved.
SUMMARY
The term high-content screening (HCS) or cell-based screening plays a major role in drug discovery and development in a pharmaceutical company and was originally employed in bioimaging-based systems. As flow cytometry technology has evolved to provide expanded color capabilities, the technology has become both a robust and an economic cell-based HCS system assaying thousands of cells per second. Flow cytometry provides several key advantages over bioimaging systems. First, this higher single-cell throughput technology allows researchers to analyze smaller population subsets with greater statistical accuracy. Second, the cell sorting can be used to collect these minor cell populations for secondary molecular testing, gaining additional data for understanding the mechanism and kinetics.
While flow cytometry provides advantages during the preclinical toxicity screening process (e.g., more information in less time), there are also challenges. First, the researchers must develop the assay. In the case of the oxidative stress model, a thorough titration of the labels was needed to optimize the assay. Any change in cell line or culture conditions would likely require similar titrations to optimize the assay. Biomarker assay development requires the availability of the appropriate antibodies and substrates to label key biomarkers. As was discussed with the CEC/CEP assay, the process may be one of elimination as well (gating out of the platelets, Tand B cells that shared the CD36 marker). The development process requires a detailed knowledge of cell lineage markers, intracellular processes, and access to labeled antibodies/ substrates for evaluation of these markers and processes. Functional substrates such as those employed in the oxidative stress study may have a fixed color or may be available in modified forms to allow selection of a "convenient" color during the assay development.
Second, the system must be tested with compounds that have a wellcharacterized toxicity profile (e.g., serotonin treatment with rats) and the outcomes must be validated with information from well-known secondary testing outcomes (e.g., gene or protein expression studies). The sorted CD36 þ /Lin À cells were tested for both culture characteristics and gene expression and showed a less definitive outcome with complex and hetergeneous response in both assays. The bone marrow study provided a more straightforward system for evaluation and validation. The flow data subset analysis information was developed using a well-characterized panel of mouse antibodies and was confirmed with a secondary test using microscopic cytology. The rhEpo treatment was known to trigger erythroblast production. The bone marrow subset data trended with similar end points between flow and cytology; however, more statistically significant variations were observed in the flow cytometry subsets.
Looking at multiple physiological end points in a single cell in the oxidative stress assay (lipid peroxidation, glutathione concentration, mitochrondial membrane potential, and finally apoptosis) provides a time-based look into a complex system. The observation propagation or abrogation of the stress effects to other compartments provides information on the mechanism of toxicity.
Ironically, the availability and complexitiy of the technology itself provide the least obstacle. Benchtop flow cytometers/analyzers are readily available in hospitals and clinics and used for a variety of routine diagnostic and monitoring applications. The platforms have evolved to provide robust, easy to operate systems with everexpanding color capabilities. The more complex cell sorting systems do require a trained operator.
Proof of the value-added aspects of the implementation of flow cytometric biomarker-based analysis in preclinical toxicity testing will be the key. Reduced time, reagent, and animal costs are one form of value addition to the pharmaceutical company. Clinicians will require evidence of the robustness of the assay and assay outcomes. However, because there is a routine collection of a variety of tissue types amenable to flow cytometry during any study, once an assay design is establised, data could be generated from logged samples for statistical analysis within a fairly reduced time frame.
